# Sirtuin-NAD Activator in Alzheimer's Disease

> **NCT05040321** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 22 (actual)

## Conditions studied

- Alzheimer's Disease (Incl Subtypes)
- Dementia

## Interventions

- **DRUG:** MIB-626
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05040321
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-01
- **Primary completion:** 2025-12-15
- **Final completion:** 2026-04-30
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05040321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05040321, "Sirtuin-NAD Activator in Alzheimer's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05040321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*